Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three months ended March 31, 2026, and 2025 [expressed in United States dollars] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)…
Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.)
Condensed consolidated interim financial statements
For the three months ended March 31, 2026, and 2025
[expressed in United States dollars]
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
[unaudited] [expressed in United States dollars]
As at
Notes
ASSETS
Current assets
Cash and cash equivalents
Other receivables
Prepaid expenses and deposits
Investments
Inventory
Digital assets - restricted
Digital assets
4
5
6
7,11
7,11
March 31,
2026
$
December 31,
2025
$
4,341,908
208,524
76,183
222,906
51,468
—
5,468,067
10,369,056
1,905,357
231,053
15,290
459,080
52,133
1,601,865
2,213,575
6,478,353
64,489
83,048
4,409,482
14,926,075
67,029
102,320
4,513,207
11,160,909
3,591,253
83,991
5,318,307
6,566,357
300,549
485,517
16,345,974
16,345,974
4,182,083
103,165
—
—
1,300,549
472,497
6,058,294
6,058,294
152,247
177,333,759
—
34,741,158
214,531
(211,846,469)
595,226
(2,015,125)
(1,419,899)
14,926,075
152,247
169,551,044
10,009
35,405,812
91,533
(198,286,170)
6,924,475
(1,821,860)
5,102,615
11,160,909
Non-current assets
Equipment, net
Right-of-use asset, net
Intangible assets, net
Total assets
LIABILITIES
Current liabilities
Trade and other payables
Lease obligations
Warrants liability
Derivative liabilities
Notes payable
Convertible debentures
8
9,20
10
12
11
12
Total liabilities
SHAREHOLDERS' EQUITY
Class A Multiple Voting Share capital
Class B Subordinate Voting Share capital
Warrants
Contributed surplus
Foreign exchange translation reserve
Accumulated deficit
Equity attributable to shareholders of the Company
Non-controlling interests
13
13
13
15
Total liabilities and shareholders’ equity
Commitments and contingencies
Subsequent events
19
23
On behalf of the Board:
/s/ Zeeshan Saeed
Zeeshan Saeed
Director
/s/ Eric Hoskins
Eric Hoskins
Director
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
1
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
[unaudited] [expressed in United States dollar, except number of shares]
2026
$
2025
$
1,320,720
626,092
892,057
127,436
2,966,305
1,328,111
1,648,350
291,272
129,690
3,397,423
Loss from operations
(2,966,305)
(3,397,423)
Interest expense (income)
Other income
Finance expense, net
Accretion and interest expense
Loss (gain) on settlement of debt
Loss in fair value of derivative liabilities and warrant liability
Unrealized loss on change in fair value of digital assets
Realized (gain) on sale of digital assets
Loss in fair value of investments
Loss on issuance of convertible debt
Net loss
9,062
(10,451)
22,854
13,267
35,802
6,954,836
1,244,943
(4,311)
235,807
2,285,450
(13,753,564)
(67,216)
(7,060)
22,168
328,448
(185,130)
3,110,436
718,827
(68,293)
—
1,490,278
(8,739,881)
122,998
(13,630,566)
(3,492)
(8,743,373)
(13,560,299)
(193,265)
(13,753,564)
(8,576,723)
(163,158)
(8,739,881)
For the three months ended March 31,
Expenses
General and administrative
External research and development fees
Share-based payments
Depreciation and amortization
Total operating expenses
Notes
17
14,20
8
12
13
10,12
7
7
6
12
Other comprehensive loss
Items that may be subsequently reclassified to loss:
Exchange gain (loss) on translation of foreign operations
Comprehensive loss
Net loss attributable to:
Equity owners of the Company
Non-controlling interests
Net (loss) per share
Basic and diluted - continuing operations
Weighted average number of shares outstanding
– basic and diluted
15
16
16
$
(3.06)
4,489,456
$
(3.53)
2,474,974
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
2
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
For the three months ended March 31, 2026, and 2025
[unaudited] [expressed in United States dollars, except number of shares]
Balance, December 31, 2024
Shares issued - convertible debt
[note 12,13]
Warrants issued [note 12]
Warrants expired [note 13]
Share-based payments [note 14]
Exercise of options [note 13,14]
Comprehensive loss for the period
Balance, March 31, 2025
Balance, December 31, 2025
Shares issued [note 13]
Shares issued - convertible debt
[note 12,13]
Shares for debt [note 13]
Warrants issued [note 12]
Warrants expired [note 13]
Share-based payments [note 14]
Exercise of RSUs [note 13,14]
Comprehensive loss for the period
Balance, March 31, 2026
Foreign
exchange
translation
reserve
$
50,795
Accumulated
deficit
$
(172,110,884)
Total
$
10,440,232
Class A shares
$
12
151,701
Class B shares
$
2,299,502
150,318,624
210,370
$
1,997,759
Contributed
surplus
$
31,072,543
—
—
—
—
—
—
—
—
—
—
—
—
12
151,701
399,071
—
—
—
12,500
—
2,711,073
2,495,090
—
—
—
70,591
—
152,884,305
—
346,806
(30,770)
—
—
—
526,406
—
—
(618,578)
—
—
—
1,379,181
—
—
618,578
291,272
(24,704)
—
31,957,689
—
—
—
—
—
(163,158)
(1,203,464)
—
—
—
—
—
(3,492)
47,303
—
—
—
—
—
(8,576,723)
(180,687,607)
2,495,090
—
—
291,272
45,887
(8,743,373)
4,529,108
42
—
152,247
—
3,887,729
1,536,341
169,551,044
5,395,700
32
—
10,009
—
35,405,812
—
(1,821,860)
—
91,533
—
(198,286,170)
—
5,102,615
5,395,700
—
—
—
—
—
—
—
42
—
—
—
—
—
—
—
152,247
16,748
370,457
—
—
—
44,415
—
5,855,690
88,978
839,896
—
—
—
1,458,141
—
177,333,759
—
—
1,249,984
(32)
—
—
—
1,249,984
—
—
—
(10,009)
—
—
—
—
—
—
—
10,009
892,057
(1,566,720)
—
34,741,158
—
—
—
—
—
—
(193,265)
(2,015,125)
—
—
—
—
—
—
122,998
214,531
—
—
—
—
—
—
(13,560,299)
(211,846,469)
88,978
839,896
—
—
892,057
(108,579)
(13,630,566)
(1,419,899)
Warrants
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
3
Noncontrolling
interests
$
(1,040,306)
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN CASH FLOWS
For the three months ended March 31, 2026, and 2025
[unaudited] [expressed in United States dollar]
2026
$
2025
(13,753,564)
(8,739,881)
127,436
—
13,267
892,057
235,807
6,954,836
2,285,450
3,599,315
1,244,943
(4,311)
35,802
129,690
25,374
328,448
291,272
—
3,110,436
1,490,278
(1,646,071)
718,827
(68,293)
(185,130)
—
22,529
(60,893)
665
(3,262,088)
(1,668,749)
414,189
99,417
(75,309)
23,386
(177,476)
(4,260,843)
Investing activities
Redemption of investments
Purchases of digital assets
Proceeds from sale of digital assets
Cash (used in) investing activities
—
(2,962,239)
68,980
(2,893,259)
1,181,499
(2,800,000)
268,293
(1,350,208)
Financing activities
Proceeds from issuance of shares, net
Proceeds from convertible debentures
Payment of lease obligation
Exercise of RSUs
Proceeds from share options exercised
Proceeds from RH loan
Repayment of Bitgo loan
Cash provided by financing activities
5,395,700
2,733,109
(21,671)
(108,579)
—
—
(1,000,000)
6,998,559
—
2,667,404
(23,325)
—
45,887
443,526
—
3,133,492
Net increase (decrease)
2,436,551
(2,477,559)
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
1,905,357
4,341,908
5,995,872
3,518,313
839,896
—
Operating activities
Net loss
Add (deduct) items not affecting cash
Depreciation and amortization
Interest expense
Accretion expense
Share-based payments
Change in fair value of investments
Change in fair value of derivative liabilities and warrant liability
Loss on issuance of convertible debt
Unrealized foreign exchange loss (gain)
Unrealized loss on change in fair value of digital assets
Realized (gain) on sale of digital assets
Loss (gain) on settlement of debt
Changes in non-cash working capital balances
Finance receivables
Other receivables
Prepaid expenses and deposits
Inventory
Trade and other payables
Cash (used in) operating activities
Non-cash transactions
Shares issued for debt
$
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
4
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Nature of business
Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (“Quantum” or the “Company”) is a biopharmaceutical company
dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging
neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in
different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum
is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS").
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying
mechanism of multiple sclerosis, in preclinical models. The Company also maintains selective R&D programs for
inflammatory diseases (FSD-PEA) and depression (Lucid-PSYCH), though these initiatives remain secondary priorities.
Quantum is also focused on the research and development of a treatment for alcohol misuse for application in hospitals
and other medical practices. Quantum maintained, through its wholly owned subsidiary, FSD Strategic Investments
Inc. ("FSD Strategic Investments"), a portfolio of strategic investments which historically represented loans secured by
residential properties. During the year ended December 31, 2025, the entire portfolio of these loan receivables was
sold to a corporation owned by the CFO of the Company. As of March 31, 2026, the Company no longer holds any
loans secured by residential properties.
The Company’s registered office is located at 1 Adelaide Street East, Suite 801. On August 15, 2024, the Company
consolidated its Class A Multiple Voting Shares and Class B Subordinate Voting Shares (each as defined hereinafter)
on a 65:1 basis and changed its name to "Quantum BioPharma Ltd." with a new trading symbol "QNTM" on both
NASDAQ and CSE.
On July 31, 2023, the Company entered into an exclusive intellectual property license agreement (the “License
Agreement”) with Celly Nutrition Corp. (“Celly”). Celly changed its name to “Unbuzzd Wellness Inc.” (“Unbuzzd”),
effective May 23, 2025. The License Agreement provides Unbuzzd access to proprietary information for the purposes
of consumer product development and marketing. The License Agreement grants Unbuzzd the rights to a proprietary
formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of
potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
The License Agreement also grants Unbuzzd rights to certain trademarks. In exchange, Quantum received
200,000,000 Unbuzzd Common Shares (as defined below) following a 2:1 share-split. The Company also received an
anti-dilution Warrant Certificate that entitles Quantum to purchase up to 25% of the Unbuzzd Common Shares deemed
outstanding less the 200,000,000 Unbuzzd Common Shares issued under the License Agreement and from time to
time as a result of any partial exercise under the anti-dilution Warrant Certificate. Quantum is also entitled to certain
license fees and royalties under the License Agreement. Through the License Agreement, Quantum acquired 34.66%
of Unbuzzd. On July 31, 2023, the Company and Unbuzzd entered into a loan agreement for gross proceeds of
C$1,000,000. The loan was funded on August 1, 2023, and accrues interest at a rate of 10% per annum. Interest is
payable annually and the loan matures on July 31, 2026. On April 3, 2024, an amendment to the loan agreement was
approved for additional gross proceeds of C$300,000. In November 2023, through the Plan of Arrangement the
Company distributed 45,712,529 of its 200,000,000 shares of Unbuzzd to its shareholders. The License Agreement
was amended and restated on August 14, 2024. The condensed consolidated interim financial statements incorporate
the assets and liabilities of Unbuzzd as of March 31, 2026, and the results of operations and cash flows for the three
months ended March 31, 2026. As of March 31, 2026, the Company had a 19.84% (December 31, 2025 – 19.84%)
ownership interest in Unbuzzd through Unbuzzd Common Shares.
5
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Subsidiaries
These condensed consolidated interim financial statements are comprised of the financial results of the Company and
its subsidiaries, which are the entities over which the Company has control. An investor controls an investee when it is
exposed, or has rights, to variable returns from its involvement with the investee and can affect those returns through
its power over the investee. The Company has the following subsidiaries:
USA
USA
Canada
Canada
Canada
Australia
Canada
%
100.00
100.00
100.00
100.00
100.00
100.00
19.84
%
100.00
100.00
100.00
100.00
100.00
100.00
19.84
Ownership
percentage as at
December 31,
2024
%
100.00
100.00
100.00
100.00
100.00
100.00
22.95
Australia
100.00
100.00
100.00
Ownership
percentage as at
Entity Name
FSD Biosciences Inc.
Prismic Pharmaceuticals Inc. (“Prismic”)
FV Pharma Inc.
Lucid Psycheceuticals Inc.
FSD Strategic Investments Inc.
FSD Pharma Australia Pty Ltd (“FSD Australia”)
Unbuzzd Wellness Inc.
Huge Biopharma Australia Pty Ltd (“Huge
Biopharma”)
Country
March 31, 2026
Ownership
percentage as at
December 31,
2025
Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not
shareholders of the Company. They are shown as a component of total equity in the condensed consolidated interim
statements of financial position, and the share of income (loss) attributable to non-controlling interests is shown as a
component of net income (loss) in the condensed consolidated interim statements of loss and comprehensive loss.
Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity
transactions.
2.
Basis of presentation
[a] Statement of compliance
These condensed consolidated interim financial statements (“financial statements’) were prepared using the same
accounting policies and methods as those used in the Company’s audited consolidated financial statements for the
year ended December 31, 2025. These financial statements have been prepared in compliance with IAS 34 – Interim
Financial Reporting. Accordingly, certain disclosures normally included in annual financial statements prepared in
accordance with IFRS® Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board
(“IASB”) have been omitted or condensed. These financial statements should be read in conjunction with the
Company’s audited consolidated financial statements for the year ended December 31, 2025.
These financial statements were approved and authorized for issuance by the Board of Directors (the “Board”) of the
Company on May 6, 2026.
6
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
[b] Functional currency and presentation currency
The financial statements of each company within the consolidated group are measured using their functional currency,
which is the currency of the primary economic environment in which an entity operates. These condensed consolidated
interim financial statements are presented in United States dollars ("USD"), which is the Company’s functional and
presentation currency for all years presented. The Company’s functional currency is the United States dollar, and the
functional currencies of its subsidiaries are as follows:
FSD Biosciences Inc.
Prismic Pharmaceuticals Inc.
FV Pharma Inc.
Lucid Psycheceuticals Inc.
FSD Strategic Investments Inc.
FSD Pharma Australia Pty Ltd
Unbuzzd Wellness Inc.
Huge Biopharma Australia Pty Ltd
United States Dollar
United States Dollar
Canadian Dollar
Canadian Dollar
Canadian Dollar
Australian Dollar
Canadian Dollar
Australian Dollar
[c] Use of estimates and judgments
The preparation of these financial statements in conformity with IFRS requires management to make estimates,
judgements and assumptions that affect the application of accounting policies and the reported amounts of assets and
liabilities, consistent with those disclosed in the audited consolidated financial statements for the year ended December
31, 2025, and described in these financial statements. Actual results could differ from these estimates.
Estimates are based on management’s best knowledge of current events and actions that the Company may undertake
in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting
estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the
period of the revision and future periods if the revision affects both current and future periods.
3.
New standards, amendments and interpretations adopted by the Company
In May 2024, the IASB issued amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments –
Disclosures. The amendments clarify the derecognition of financial liabilities and introduce an accounting policy option
to derecognize financial liabilities that are settled through an electronic payment system. The amendments also clarify
how to assess the contractual cash flow characteristics of financial assets that include environmental, social and
governance (ESG)-linked features and other similar contingent features and the treatment of non-recourse assets and
contractually linked instruments (CLIs). Further, the amendments mandate additional disclosures in IFRS 7 for financial
instruments with contingent features and equity instruments classified at FVOCI. There was no material impact on the
consolidated interim financial statements.
The IASB issued IFRS 18 Presentation and Disclosure in Financial Statements, which replaces IAS 1 Presentation of
Financial Statements, effective on January 1, 2027. Earlier application is permitted. The objective of IFRS 18 is to set
out requirements for the presentation and disclosure of information in general purpose financial statements to help
ensure they provide relevant information that faithfully represents an entity’s assets, liabilities, equity, income and
expenses. IFRS 18 applies to all financial statements that are prepared and presented in accordance with IFRSs.
Standards for recognizing, measuring, and disclosing specific transactions are addressed in other Standards and
Interpretations.
The Company will assess the impact on the consolidated interim financial statements when applicable.
7
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
4.
Other receivables
The Company’s other receivables are comprised of the following as at:
March 31, 2026
$
165,946
42,578
—
—
208,524
Sales tax recoverable
Interest receivable
Other receivables
Subscription receivables
December 31, 2025
$
102,714
73,575
1,712
53,052
231,053
Prepaid expenses and deposits
The Company’s prepaid expenses and deposits include the following:
March 31, 2026
$
56,455
19,728
76,183
Insurance
Other prepaids and deposits
December 31, 2025
$
2,201
13,089
15,290
Investments
The following tables outline changes in investments during the period ended March 31, 2026:
Entity
A2ZCryptoCap Inc.
Royal Bank of Canada
Gamestop
Genius Group Ltd
JZR Gold
Instrument
Note
Shares
GIC
Shares
Shares
Warrants
(i)
(ii)
(iii)
(iv)
(v)
Balance at
December 31, 2025
$
3,794
21,889
40,158
21,906
371,333
459,080
Change in fair
value through
profit or loss
$
(64)
5,922
(9,499)
(232,166)
(235,807)
Effects of
foreign
exchange
$
(367)
(367)
Current
Non-current
Balance at
March 31, 2026
$
3,730
21,522
46,080
12,407
139,167
222,906
222,906
222,906
(i) On June 23, 2022, the Company acquired 80,000 shares of A2ZCryptoCap Inc. for C$0.10 per share. As at March
31, 2026, the fair value of the shares was determined based on the quoted market price of the shares of C$0.065 per
share (December 31, 2025 – C$0.065).
ii) During the year ended December 31, 2024, the Company purchased four GICs for a total amount of C$4,030,000
from RBC with maturity dates ranging from February 14, 2025, to September 12, 2025. The GICs pay variable interest
ranging from 4.20% to 4.95% per annum. As of March 31, 2026, the total balance outstanding was C$30,000
(December 31, 2025 – C$30,000) as three GICs out of the four were effectively redeemed during the year ended
December 31, 2024.
iii) On July 18, 2025, the Company purchased 2,000 shares of GameStop Corp. (NYSE: GME) for a total amount of
$48,516 (C$66,561) for $23.55 per share. As at March 31, 2026, the fair value of the shares was determined based on
the quoted market price of $23.04 per share resulting in a gain on change in fair value of $5,922 for the three months
ended March 31, 2026.
8
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
iv) On July 25, 2025, the Company purchased 40,000 shares of Genius Group Limited (AMEX: GNS) for a total amount
of $49,009 (C$67,237) for a weighted average price of $1.20 per share. On July 28, 2025, the Company sold 1,871
shares of GNS for a total amount of $2,217 (C$3,043). As at March 31, 2026, the fair value of the remaining 38,129
shares was determined based on the quoted market price of $0.33 per share resulting in a loss on change in fair value
of $9,499 for the three months ended March 31, 2026.
v) On July 22, 2025, the Company acquired 1,666,667 units at a price of C$0.30 per unit of JZR Gold Inc (“JZR”) for
$364,800 (C$500,000). Each unit is comprised of one common share in the capital of JZR and one non-transferable
common share purchase warrant to acquire one common share at a price of C$0.40 per warrant share.
•
•
The Company sold 1,666,667 common shares on December 10, 2025, with a fair value of $283,097
(C$391,667), at C$0.235 per share, resulting in a loss on change in fair value of $68,936 prior to the date of
sale. As of March 31, 2026, there were no outstanding shares.
The 1,666,667 associated warrants, valued at $150,639 on acquisition date using the Black Scholes model,
had a fair value of $139,167 as at March 31, 2026, resulting in a loss on change in fair value of $232,166 for
the three months ended March 31, 2026.
The fair value of the warrants was determined using the Black-Scholes option pricing model and the following
assumptions as at the following dates:
Share price (CDN)
Exercise price
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
July 22, 2025
$0.460
$0.29
2.78%
2.00
135.64%
December 31, 2025
$0.465
$0.29
2.55%
1.56
140.17%
March 31, 2026
$0.245
$0.29
2.79%
1.31
140.17%
Digital assets
(a) The changes in the digital assets balance for the following periods are as follows:
Bitcoin
Solana
ETH
XRP
SUI
LINK
9
January 1, 2026
Balance
$
2,287,611
1,336,507
54,749
—
22,683
113,890
3,815,440
Additions
$
2,365,239
400,000
—
112,000
—
85,000
2,962,239
Disposition
s
$
(64,669)
—
—
—
—
—
(64,669)
Unrealized (loss)
gain
$
(700,371)
(457,982)
(15,937)
(29,647)
(8,323)
(32,683)
(1,244,943)
March 31, 2026
Balance
$
3,887,810
1,278,525
38,812
82,353
14,360
166,207
5,468,067
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Bitcoin
Dogecoin
Solana
ETH
XRP
SUI
LINK
January 1, 2025
Balance
$
356,877
154,314
350,039
—
—
—
—
861,230
Additions
$
2,827,102
200,000
2,052,166
132,093
150,000
50,000
221,215
5,632,576
Dispositions
$
(647,000)
(401,000)
(661,503)
(47,000)
(150,000)
—
—
(1,906,503)
Unrealized (loss)
gain
$
(249,368)
46,686
(404,195)
(30,344)
—
(27,317)
(107,325)
(771,863)
December 31, 2025
Balance
$
2,287,611
—
1,336,507
54,749
—
22,683
113,890
3,815,440
Digital currency prices are affected by various forces including global supply and demand, interest rates, exchange
rates, inflation or deflation and the global political and economic conditions. Digital assets have a limited history, and
the fair value historically has been very volatile. The Company may not be able to liquidate its inventory of digital assets
currency at its desired price if required. The Company has recognized an unrealized loss in change in fair value of
$1,244,943 for the three months ended March 31, 2026 (2025 - $718,827).
During the three months ended March 31, 2026, the Company invested an additional $2,962,239 in digital assets. The
Company also sold $64,669 in digital assets for total gross proceeds of $68,980 and recognized a gain on sale of digital
assets of $4,311 for the three months ended March 31, 2026 (2025 - $68,293).
The following table presents the Company’s digital assets, measured at fair value less and categorized into levels of
the fair value hierarchy on the condensed consolidated interim statements of financial position as at the following:
As at March 31, 2026
Digital assets,
at fair value
Digital coins
Level 1
Quoted market
price
$
—
Level 2
Valuation technique - observable
market inputs
$
5,468,067
Level 3
Valuation technique - unobservable
market inputs
$
—
Level 2
Valuation technique - observable
market inputs
$
3,815,440
Level 3
Valuation technique - unobservable
market inputs
$
—
As at December 31, 2025
Digital assets,
at fair value
Digital coins
10
Level 1
Quoted market
price
$
—
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
8.
Intangible assets
Intangible assets as at March 31, 2026, are as follows:
Cost
As at December 31, 2025, and March 31, 2026
Lucid
$
6,314,571
Accumulated amortization
As at December 31, 2025
Amortization
As at March 31, 2026
$
1,801,364
103,725
1,905,089
Net book value
As at March 31, 2026
As at December 31, 2025
4,409,482
4,513,207
The Company’s intangible asset for Lucid represents the license agreement with the University Health Network giving
the Company world-wide exclusive rights to the Lucid-MS compound and related patents.
9.
Trade and other payables
Trade and other payables consist of the following as at:
Trade payables
Accrued liabilities (i)
March 31, 2026
$
1,978,210
1,613,043
3,591,253
December 31, 2025
$
1,981,851
2,200,232
4,182,083
March 31, 2026
$
215,120
134,788
853,942
409,193
1,613,043
December 31, 2025
$
35,770
774,223
981,046
409,193
2,200,232
(i) Accrued liabilities consist of the following as at:
External research and development fees
Operational expenses
Professional and other fees
Accrued interest
11
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
10. Warrants Liability
[a] December 2024 Warrants
During the year ended December 31, 2024, the Company issued warrants attached to its convertible debenture (Note
12).
The Company determined that these warrants were exchangeable into a variable number of shares due to foreign
exchange, and as such, the warrants were classified as financial liabilities measured at fair value through profit or loss
(“FVTPL”). The Company used the Black-Scholes pricing model to estimate fair value. Expected volatility was based
on an evaluation of the historical volatility of the Company’s share price. The risk-free interest rate for the life of the
warrants was based on the yields available on government benchmark bonds with a term approximating the remaining
term of the warrants. The life of the warrants was based on the contractual term. The fair value of the warrant liability
as at December 13, 2024, the date of issuance was $245,147. The fair value of the warrants as of March 31, 2026,
was $Nil (December 31, 2025 - $Nil) resulting in a loss on change in fair value of $Nil for the three months ended March
31, 2026 (2025 - $311,128). On June 25, 2025, 80,000 total warrants outstanding were exercised on a cashless basis
into 66,315 Class B Subordinate Voting Shares.
The fair values were determined using the Black-Scholes option pricing model and the following assumptions as at:
Share price (CAD)
Exercise price (CAD)
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
Foreign exchange rate
December 13, 2024
$5.80
$7.00
2.97%
5.00
104.39%
0.70
December 31, 2024
$5.20
$7.00
2.96%
4.95
104.52%
0.70
June 25, 2025
$33.48
$7.00
2.940%
4.47
118.86%
0.73
[b] January 2025 Warrants
On January 20, 2025, the Company issued warrants attached to its convertible debenture (Note 12). The fair value of
the warrant liability at the date of issuance on January 20, 2025, was $405,656. The fair value of the warrants as of
March 31, 2026 was $Nil (December 31, 2025 - $Nil) resulting in a loss on change in fair value of $Nil for the three
months ended March 31, 2026 (2025 - $623,445), On June 25, 2025, the 152,577 total warrants outstanding were
exercised on a cashless basis into 133,002 Class B Subordinate Voting Shares.
The fair values were determined using the Black-Scholes option pricing model and the following assumptions as at:
Share price (CAD)
Exercise price (CAD)
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
Foreign exchange rate
12
January 20, 2025
$4.90
$5.25
2.99%
5.00
106.90%
0.70
June 25, 2025
$33.48
$5.25
2.90%
4.58
118.86%
0.73
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
[c] March 6, 2025 Warrants
On March 6, 2025, the Company issued warrants attached to its convertible debenture (Note 12). The fair value of the
warrant liability as at date of issuance on March 6, 2025, was $38,702. The fair value of the warrants as of March 31,
2026 was $Nil (December 31, 2025 - $Nil) resulting in a loss on change in fair value of $Nil for the three months ended
March 31, 2026 (2025 - $31,110). On June 25, 2025, the 10,309 total warrants outstanding were exercised on a
cashless basis into 8,986 Class B Subordinate Voting Shares.
The fair values were determined using the Black-Scholes option pricing model and the following assumptions as at:
Share price (CAD)
Exercise price (CAD)
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
Foreign exchange rate
March 6, 2025
$6.44
$5.25
2.72%
5.00
115.20%
0.70
June 25, 2025
$33.48
$5.25
2.90%
4.70
118.86%
0.73
[d] March 28, 2025 Warrants
On March 28, 2025, the Company issued warrants attached to its convertible debenture (Note 13). The fair value of
the warrant liability as at date of issuance was $1,218,875 (Note 13). The fair value of the warrants as of March 31,
2026 was $Nil (December 31, 2025 - $Nil) resulting in a loss on change in fair value of $Nil for the three months ended
March 31, 2026 (2025 - $Nil). On June 24, 2025, 8,500 warrants were exercised at a price of $7.00 for total gross
proceeds of $43,257 (C$59,500). The remaining 175,420 warrants were exercised on a cashless basis into 137,927
Class B Subordinate Voting Shares on various dates between June 25, 2025, to July 31, 2025.
The fair values were determined using the Black-Scholes option pricing model and the following assumptions as at:
Share price (CAD)
Exercise price (CAD)
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
Foreign exchange rate
13
March 28, 2025
$11.08
$7.00
2.61%
5.00
116.80%
0.70
June 25, 2025 – July 31, 2025
$25.89 - $33.48
$7.00
2.90% - 3.01%
4.67 - 4.77
118.79% - 118.86%
0.72 - 0.74
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
[e] March 20, 2026 Warrants
On March 20, 2026, the Company issued warrants attached to its convertible debenture (Note 12). The fair value of
the warrant liability as at date of issuance was $2,279,221 (Note 13). The fair value of the warrants as of March 31,
2026, was $5,318,307 resulting in a loss on change in fair value of $3,039,086 for the three months ended March 31,
2026.
The fair values were determined using the Black-Scholes option pricing model and the following assumptions as at:
Share price (CAD)
Exercise price (CAD)
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
Foreign exchange rate
March 20, 2026
$3.07
$3.75
3.03%
5.00
136.65%
0.729
March 31, 2026
$6.73
$3.75
2.79%
4.97
142.21%
0.717
As at March 31, 2026, the warrant liability outstanding is $5,318,307 (December 31, 2025 - $Nil).
11. Notes payable
On June 4, 2025, the Company obtained a $1,000,000 loan from its primary crypto assets custodian, BitGo Prime,
LLC., secured by 14.87584 Bitcoin units pledged as collateral. As at March 31, 2026, the total Bitcoin units pledged
were Nil (December 31, 2025 - 18.32), valued at $Nil (December 31, 2025 - $1,601,865).
During the three months ended March 31, 2026, the Company repaid the outstanding principal balance of $1,000,000,
thereby extinguishing the loan. During the term of the loan, the Company satisfied all required interest obligations
through monthly installments, which aggregated to a total interest amount of $74,750 over the duration of the borrowing
period. As of March 31, 2026, no amounts remain outstanding under this agreement.
As at March 31, 2026, the Company has an outstanding notes payable balance of $300,549 (December 31, 2025 $300,549) which was assumed on the acquisition of Prismic and is due on demand.
- Convertible debentures
December 2024 Debentures
In December 2024, the Company issued a total of 1,000 convertible debenture units of the Company (the “2024
Debenture Units”) at a price of C$1,000 per 2024 Debenture Unit for total gross proceeds of $702,700 (C$1,000,000)
(“Tranche 1 and 2”). The December 2024 Debenture Units were issued to an entity, which is owned by a family member
of an executive officer of the Company. Each 2024 Debenture Unit consisted of (i) one convertible debenture having a
face value of C$1,000 (each a “December 2024 Debenture”); and (ii) 80 class B Subordinate Voting Share purchase
warrants (each a “December 2024 Warrant”) exercisable for 80 Class B subordinate voting shares in the Company
(each, a “Subordinate Voting Share”). The Debentures matured 36 months from the date of issuance (the "December
2024 Debenture Maturity Date") and had an interest rate of 1.25% per month, beginning on the date of issuance and
payable in cash on the last day of each calendar quarter. If the holder (“2024 Denture Holder”) of the December 2024
Debenture elected, in its sole and absolute discretion, interest could have been paid in Shares at the Conversion Price
in effect on the date of payment. The principal sum of the Debentures, or any portion thereof, and any accrued but
unpaid interest, could have been converted into class B Shares at a conversion price of C$6.25 per Share subject to
adjustment (“Conversion Price”). Each December 2024 Warrant entitled the holder to acquire one a “December 2024
14
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Warrant Share" at a price of C$7.00 per December 2024 Warrant Share, for a period of five years from the date of
issuance. If the entire amount owing on the December 2024 Debenture was converted within 6 months of the issuance
date, the Holder was entitled to receive a cash amount equal to half the sum of all payments of interest on the December
2024 Debenture that would be due through to the December 2024 Debenture Maturity Date, which the holder could
have converted all of any part into Class B Subordinate Voting Shares at the Conversion Price.
The Company could have redeemed the December 2024 Debentures at any time prior to maturity, in whole or in part,
upon fifteen days’ notice and payment of certain penalties as applicable. The December 2024 Debenture was
determined to be a financial instrument comprising a host debt component, a conversion feature and a warrant
component which are both considered to be embedded derivatives due to variable consideration payable upon
conversion caused by foreign exchange. On initial recognition, the fair value of the embedded derivatives was
calculated first, with the residual value being assigned to the host financial liability. The initial fair value of the warrants
was $245,147 (Note 10).
The fair value of the conversion feature was determined by using with-and-without method (“with-and-without method’)
that considered changes in expected cash flows due to the conversion. The model included all terms of the December
2024 Debenture described above as well as the probability of conversion, the impact of default barrier and the implied
credit spread of the Company. The fair value of the conversion feature as at December 13, 2024, the date of issuance,
was $320,000. The fair value of the conversion feature as at March 31, 2026, was $Nil (December 31, 2025 - $Nil)
resulting in a loss on change in fair value for the three months ended March 31, 2026 of $Nil (2025 - $$631,360). The
entire amount of the December 2024 Debenture was converted on May 5, 2025, and May 23, 2025.
The fair values were determined using the assumptions below:
Share price (CAD)
Conversion price (CAD)
Expected Volatility
Risk free interest rate
Expected life
Credit Spread
Foreign exchange rate
December 13, 2024
$
5.85
$
6.25
98.04%
2.78%
3.00
12.25%
0.7025
December 31, 2024
$
5.20
$
6.25
100.68%
2.70%
2.95
12.25%
0.6952
$
$
May 5, 2025
11.86
6.25
109.68%
2.83%
2.64
25%
0.7240
$
$
May 23, 2025
15.89
6.25
111.59%
2.83%
2.60
25%
0.7270
As of March 31, 2026, the Company had the following December 2024 Debenture balance outstanding:
Proceeds
Value of conversion option
Value of warrants (Note 10 [b])
Initial recognition of debt
Accretion expense
Balance, December 31, 2024
Accretion expense
Balance, date of conversion, May 5, 2025
Amount converted
Balance, May 5, 2025
Accretion expense
Balance, date of conversion, May 23, 2025
Amount converted
Balance, December 31, 2025 and March 31, 2026
15
$
$
$
$
$
$
$
702,700
(320,000)
(245,147)
137,553
14,560
152,113
7,426
159,539
(81,079)
78,460
2,630
81,090
(81,090)
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
January 2025 Debentures
On January 20, 2025, the Company closed the third tranche of the December 2024 Offering (“Tranche 3”) and issued
1,480 December 2024 Debenture Units for aggregate gross process of $1,032,744 (C$1,480,000). The Tranche 3
December 2024 Debenture Units were issued to an entity, which is owned by a family member of an executive officer
of the Company. Tranche 3 was completed under amended terms, including a reduced conversion price of C$4.85 per
share, an increased warrant ratio of 103.093 December 2024 Warrants per December 2024 Debenture Unit, and a
reduced exercise price of C$5.25 per December 2024 Warrant Share.
On initial recognition, the fair value of the embedded derivatives was calculated first, with the residual value being
assigned to the host financial liability. The initial fair value of the warrants was $405,656 (Note 10). The fair value of
the conversion feature was determined by using with-and-without method. The fair value of the conversion feature as
at January 20, 2025, as at the date of issuance, was $599,770.
On February 7, 2025, the debt holder converted a partial amount of the December 2024 Debenture into an aggregate
of 152,577 Class B Subordinate Voting Shares (Note 13). On February 26, 2025, the debt holder converted the
remaining amount of the December 2024 Debenture into an aggregate amount of 221,237 Class B Subordinate Voting
Shares (Note 13). Thus, the total amount of Class B Subordinate Voting Shares converted under the December 2024
Debenture was 373,814.
The fair value of the conversion feature as at dates of conversion on February 7 and February 26, 2025, was
$2,912,862, and $656,513, respectively, resulting in a total loss on change in fair value of $1,513,174 for the period
ended March 31, 2025.
The fair values were determined using the assumptions below:
Share price (CAD)
Conversion price (CAD)
Expected Volatility
Risk free interest rate
Expected life
Credit Spread
Foreign exchange rate
$
$
January 20, 2025
4.90
4.85
93.66%
2.99%
3.00
25%
0.6978
$
$
February 7, 2025
16.16
4.85
105.28%
2.63%
2.95
25%
0.6994
$
$
February 26, 2025
8.27
4.85
104.91%
2.70%
2.90
25%
0.6974
The Company also incurred a total of $210,872 interest penalties for early conversion of the debentures. This amount
was transferred to share capital.
16
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
As of March 31, 2026, the Company had the following January 2025 Debenture balance outstanding:
Proceeds
Value of conversion option
Value of warrants (Note 10 [c])
Initial recognition of debt – January 20, 2025
Accretion expense
Balance, date of conversion – February 7, 2025
Amount converted
Balance, February 7, 2025
Accretion expense
Balance, date of conversion, February 26, 2025
Amount converted
Balance, December 31, 2025, and March 31, 2026
$
$
$
$
$
$
1,032,744
(599,770)
(405,656)
27,318
14,186
41,504
(27,845)
13,659
7,519
21,178
(21,178)
March 6, 2025 Debentures
On March 6, 2025, the Company closed the fourth tranche of the December 2024 Offering (“Tranche 4”) and issued
100 December 2024 Debenture Units for aggregate gross process of $69,890 (C$100,000). Tranche 4 was completed
under the same terms as the amended December 2024 Debentures, including a conversion price of C$4.85 per share,
an increased warrant ratio of 103.093 December 2024 Warrants per December 2024 Debenture Unit, and an exercise
price of C$5.25 per December 2024 Warrant share.
On initial recognition, the fair value of the embedded derivatives was calculated first, with the residual value being
assigned to the host financial liability. The initial fair value of the warrants was $38,702 (Note 10). The fair value of the
conversion feature was determined by using with-and-without method. The fair value of the conversion feature as at
March 6, 2025, the date of issuance, was $30,000.
On March 25, 2025, the debt holder converted the December 2024 Debenture into an aggregate of 25,257 Class B
Subordinate Voting Shares (Note 13). The fair value of the conversion feature as at date of conversion on March 25,
2025, did not change from the value on the date of issuance.
The fair value was determined using the assumptions below:
Share price (CAD)
Conversion price (CAD)
Expected Volatility
Risk free interest rate
Expected life
Credit Spread
Foreign exchange rate
$
$
March 6, 2025
6.44
4.85
106.09%
2.72%
3.00
25%
0.6989
There was no change in accretion amount from date of issuance to date of conversion.
17
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
As of March 31, 2026, the Company had the following March 6, 2025, Debenture balance outstanding:
Proceeds
Value of conversion option
Value of warrants (Note 10 [d])
Initial recognition of debt - March 6, 2025 and date of conversion,
March 25, 2025
Amount converted
Balance, December 31, 2025 and March 31, 2026
$
69,890
(30,000)
(38,702)
$
1,188
(1,188)
$
March 28, 2025 Debentures
On March 28, 2025, the Company closed the final tranche of the December 4, 2024 Offering (“Tranche 5”) and issued
2,420 December 2024 Debenture Units for aggregate gross proceeds of $1,683,352 (C$2,420,000). Tranche 5 was
completed under amended terms, including an increased conversion price of C$6.60 per share, a reduced warrant ratio
of 76 December 2024 Warrants per December 2024 Debenture Unit, and an increased exercise price of C$7.00 per
December 2024 Warrant Share.
On initial recognition, the fair value of the embedded derivatives was calculated first, with the residual value being
assigned to the host financial liability. The initial fair value of the warrants is $1,218,875 (Note 10). The fair value of the
conversion feature was determined by using with-and-without method. The fair value of the conversion feature as at
March 28, 2025, the date of issuance, was $1,954,755. As the fair value of warrants and conversion feature were higher
than the principal debt amount on the date of issuance, there was a loss on issuance of convertible debt of $1,490,278
for the three months ended March 31, 2025.
Of the 2,420 December 2024 Debenture Units issued, 330 December 2024 Debenture Units had been issued to a
related party of the Company, which is an entity controlled by a director of the Company, 330 December 2024
Debenture Units had been issued to an entity, which is controlled by a family member of a director of the Company,
and 1,060 December 2024 Debenture Units had been issued to an entity, which is owned by a family member of an
executive officer of the Company. Of the total loss on issuance of convertible debt of $1,490,278, $1,059,206 was
allocated to related parties, therefore disclosed as part of the share-based compensation balance in the key
management disclosure for the three months ended March 31, 2025 (Note 20).
The December 2024 Debentures were converted into Class B Subordinate Voting Shares on various dates, and a total
of 376,347 Class B Subordinate Voting Shares were issued during the year ended December 31, 2025.
The fair values of the conversion feature and assumptions, on the date of issuance and conversions were as follows:
Share price (CAD)
Conversion price (CAD)
Expected Volatility
Risk free interest rate
Expected life
Credit Spread
Foreign exchange rate
Conversion value
18
March 28, 2025
$11.08
$6.60
108.64%
2.61%
3.00
25%
0.6952
$1,954,755
April 10, 2025
$9.38
$6.60
107.93%
2.81%
3.00
25%
0.7135
$2,029,678
April 23, 2025
$9.53
$6.60
108.27%
2.84%
2.98
25%
0.7209
$2,001,723
May 12, 2025
$12.77
$6.60
106.62%
2.80%
2.93
25%
0.7144
$2,612,294
May 21, 2025
$17.03
$6.60
107.09%
2.97%
2.9
25%
0.7221
$3,404,094
June 5, 2025
$18.78
$6.60
107.90%
2.86%
2.86
25%
0.7321
$3,740,737
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
The Company had the following March 28, 2025 Debenture balance outstanding
Proceeds
Value of conversion option
Value of warrants (Note 10 [e])
Loss on issuance of convertible
Initial recognition of debt - March 28, 2025
$
$
1,683,352
(1,954,755)
(1,218,875)
1,490,278
March 20, 2026 Debentures
On March 20, 2026, the Company issued 3,750 debenture units of the Company (“March 2026 Debenture Units”) for
aggregate gross proceeds of $2,733,109 (C$3,750,000). Each March 2026 Debenture Unit consists of (i) one secured
convertible debenture having a face value of C$1,000.00 (the “Principal Amount”) and (ii) 333.33 Class B Subordinate
Voting Shares purchase warrants (the “Warrants”).
Each March 2026 Debenture Unit will mature 24 months from the date of issuance and shall bear interest at a rate of
1.25% per month, beginning on the date of issuance and payable in cash on the last day of each calendar quarter,
starting June 30, 2026. The Principal Amount of the debentures, or any portion thereof, and any accrued but unpaid
interest, may be converted into Class B Subordinate Voting Shares at a conversion price of C$3.00 per Class B
Subordinate Voting Share. Each Warrant shall entitle the holder to acquire one additional Class B Subordinate Voting
Shares at a price of C$3.75 per warrant share, for a period of five years from the date of issuance.
On initial recognition, the fair value of the embedded derivatives is calculated first, with the residual value being
assigned to the host financial liability. The initial fair value of the warrants is $2,279,221 (Note 10). The fair value of the
conversion feature is determined by using with-and-without method. The fair value of the conversion feature as at
March 20, 2026, the date of issuance was $2,739,338. As the fair value of warrants and conversion feature are higher
than the principal debt amount on the date of issuance, there was a loss on issuance of convertible debt of $2,285,450
for the three months ended March 31, 2026.
Of the 3,750 March 2026 Debenture Units, 300 March 2026 Debenture Units were issued to a related party of the
Company, who is a director of the Company, and 1,400 March 2026 Debenture Units were issued to an entity, which
is owned by a family member of the CFO of the Company (Note 20).
On March 31, 2026, a debt holder converted a partial amount of the March 2026 Debenture Units, consisting of
C$49,998 and C$247 of unpaid accrued interest, into an aggregate amount of 16,748 Class B Subordinate Voting
Shares (Note 13).
The fair value inputs and assumptions for the calculation of the conversion feature, on the date of issuance and on the
date of conversion, are as follows:
Share price (CAD)
Conversion price (CAD)
Expected Volatility
Risk free interest rate
Expected life
Credit Spread
Foreign exchange rate
Conversion value
March 20, 2026
$3.07
$3.00
136.65%
3.03%
2.00
25%
0.729
$2,739,338
March 31, 2026
$6.73
$3.00
142.21%
2.79%
1.97
25%
0.717
$6,655,088
As of March 31, 2026, the Company had the following March 2026 Debenture balance outstanding.
19
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Proceeds
Value of conversion option
Value of warrants (Note 10 [f])
Loss on issuance of convertible
Initial recognition of debt – March 20, 2026
$
$
2,733,109
(2,739,338)
(2,279,221)
2,285,450
As at March 31, 2026, the Company accrued interest expense of $13,020 outstanding as part of the March 2026
Debenture Units. As at March 31, 2026, the Company has a derivative liabilities balance of $6,566,357 (December 31,
2025 - $Nil) and convertible debentures balance of $13,020 (December 31, 2025 - $Nil).
Convertible Debentures issued by Unbuzzd
Tranche 1
In April 2025, Unbuzzd issued a total of 172 unsecured convertible debenture units of Unbuzzd (each an ‘Unbuzzd
Debenture’) at a price of US$1,000 per Unbuzzd Debenture for gross proceeds of $177,416. Each Unbuzzd Debenture
includes an interest rate at 8% per annum, accruing annually and is added to the principal of the Unbuzzd Debenture
when accrued, payable upon the earlier of April 15, 2027 (the “Unbuzzd Maturity Date”) or date of conversion. If
Unbuzzd has not completed a Liquidity Event (defined below) on or before April 15, 2026, an additional 10% per annum
(for an aggregate of 18%) will begin to accrue monthly starting April 16, 2026.
The Unbuzzd Debenture holder has the right, from time to time and at any time while any portion of the principal amount
or any accrued and unpaid interest on the Unbuzzd Debenture is outstanding, to convert all or any portion of the
outstanding principal amount and interest into units of Unbuzzd (each, a “Unbuzzd Unit”) at the Unbuzzd Conversion
Price (defined below).
Each Unbuzzd Unit consists of one (1) common share in the capital of Unbuzzd (each, a “Unbuzzd Common Share”)
and (ii) one half of a one (1/2) Unbuzzd Common Share purchase warrant (each whole warrant, a “Unbuzzd Warrant”).
Each Unbuzzd Warrant entitles the holder to acquire one additional Unbuzzd Common Share on or before April 15,
2027 for 115% of the Unbuzzd Liquidity Event Price.
The conversion price (“Unbuzzd Conversion Price”) is equal to:
i)
ii)
iii)
US$0.15 per Unbuzzd Unit;
In the event of an Unbuzzd Qualified Financing, then 0.80 multiplied by the Unbuzzd Qualified Financing
Price; or
In the event of an Unbuzzd Liquidity Event, then 0.80 multiplied by the Unbuzzd Liquidity Event Price:
Following the completion of an Unbuzzd Qualified Financing or immediately prior to an Unbuzzd Liquidity Event,
Unbuzzd shall have the option to force a conversion of the principal amount of each Unbuzzd Debenture, and if Unbuzzd
elects, the accrued but unpaid Interest, into Unbuzzd Units at the Unbuzzd Conversion Price. Unbuzzd Qualified
Financing means the completion of an equity financing by Unbuzzd, including but not limited to a Series A financing,
after the date hereof for aggregate gross proceeds of not less than US$2,000,000. Unbuzzd Liquidity Event means a
takeover transaction or going public transaction.
20
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Tranche 2
On July 7, 2025, Unbuzzd issued a total of 50 unsecured convertible debenture units at a price of US$1,000 per
Debenture for gross proceeds $50,000 with the same terms as Tranche 1.
Tranche 3
In August and September 2025, Unbuzzd issued a total of 92.50 unsecured convertible debenture units (each, an
‘Unbuzzd Debenture’) at a price of US$1,000 per Debenture for gross proceeds of $92,500 with the same terms as
Tranche 1.
Tranche 4
In October and November 2025, Unbuzzd issued a total of 35 unsecured convertible debenture units of Unbuzzd (each
an ‘Unbuzzd Debenture’) at a price of US$1,000 per Unbuzzd Debenture for gross proceeds of $35,000. Each Unbuzzd
Debenture includes an interest rate at 8% per annum, accruing annually and is added to the principal of the Unbuzzd
Debenture when accrued, payable upon the earlier of December 31, 2027 (the “Unbuzzd Maturity Date”) or date of
conversion.
The Unbuzzd Debenture holder has the right, from time to time and at any time while any portion of the principal amount
or any accrued and unpaid interest on the Unbuzzd Debenture is outstanding, to convert all or any portion of the
outstanding principal amount and interest into units of Unbuzzd (each, a “Unbuzzd Unit”) at the Unbuzzd Conversion
Price (defined below).
Each Unbuzzd Unit consists of one (1) common share in the capital of Unbuzzd (each, a “Unbuzzd Common Share”)
and (ii) one half of a one (1/2) Unbuzzd Common Share purchase warrant (each whole warrant, a “Unbuzzd Warrant”).
Each Unbuzzd Warrant entitles the holder to acquire one additional Unbuzzd Common Share on or before December
31, 2027 for 115% of the Unbuzzd Liquidity Event Price.
The conversion price (“Unbuzzd Conversion Price”) is equal to:
i)
ii)
iii)
US$0.15 per Unbuzzd Unit;
In the event of an Unbuzzd Qualified Financing, then 0.80 multiplied by the Unbuzzd Qualified Financing
Price; or
In the event of an Unbuzzd Liquidity Event, then 0.80 multiplied by the Unbuzzd Liquidity Event Price:
Following the completion of an Unbuzzd Qualified Financing or immediately prior to an Unbuzzd Liquidity Event,
Unbuzzd shall have the option to force a conversion of the principal amount of each Unbuzzd Debenture, and if Unbuzzd
elects, the accrued but unpaid Interest, into Unbuzzd Units at the Unbuzzd Conversion Price. Unbuzzd Qualified
Financing means the completion of an equity financing by Unbuzzd, including but not limited to a Series A financing,
after the date hereof for aggregate gross proceeds of not less than US$5,000,000. Unbuzzd Liquidity Event means a
takeover transaction or going public transaction.
The convertible debenture was determined to be financial instruments comprising a host debt component, a conversion
feature and a warrant component which are both considered to be embedded derivatives due to variable consideration
payable upon conversion caused by foreign exchange as well as failing the fixed-to-fixed clause for classifying as
equity. On initial recognition, the fair value of the embedded derivatives is calculated first, with the residual value being
assigned to the host financial liability.
21
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Conversion feature
The fair value of the conversion feature is determined by using with-and-without method that considers the change in
expected cash flows due to the conversion. The model includes all terms of the convertible debenture described above
as well as the probability of conversion and the implied credit spread of Unbuzzd. Expected volatility was estimated by
using historical volatility of Quantum as Unbuzzd considers it comparable for its own volatility history. The share price
of $0.00017 (C$0.00025) was deemed reasonable by management based on Unbuzzd’s latest financing price with
arms-length parties. The fair value of the conversion feature as at April 15, 2025, July 7, 2025, August/September
2025, and October/November 2025, the dates of issuances were $Nil. The fair value of the conversion feature as at
March 31, 2026, was also $Nil (December 31, 2025 - $Nil), resulting in no change in fair value during the period for all
tranches. The fair values were determined using the assumptions below:
April 15, 2025
July 7, 2025
$0.00017
$0.15000
119.78%
2.54%
2.00
25%
1.39
$0.00017
$0.15000
132.95%
2.69%
1.77
25%
1.37
Share price (USD)
Conversion price (USD)
Expected Volatility
Risk free interest rate
Expected life (years)
Credit Spread
Foreign exchange rate
August/Septemb
er 2025
$0.00017
$0.15000
136.82%-141.83%
2.50%-2.69%
1.59-1.71
25%
1.38
October/
November2025
$0.00017
$0.15000
124.06%-127.63%
2.46%-2.47%
2.16-2.28
25%
1.40
December 31,
2025
$0.00017
$0.15000
135.29%
2.55%
1.31-2.00
25%
1.37
March 31,
2026
$0.00017
$0.15000
149.24%-162.46%
2.79%
1.06-1.78
25%
1.39
Secured debentures
On July 25, 2025, Unbuzzd issued a total of 110 secured convertible debenture units (each an “Unbuzzd Secured
Debenture”) at a subscription price of US$1,000 per Debenture. Each Debenture Unit consists of (i) a USD$1,111.11
principal amount secured convertible debenture and (ii) such number of common share purchase Unbuzzd Warrants
for gross proceeds of $122,222. The Unbuzzd Secured Debentures will mature (the “Unbuzzd Secured Debenture
Maturity Date”) on the earlier of (i) July 25, 2026, or (ii) the date that is one month following the closing of a Qualified
Financing, as defined below.
Each unit consists of one (1) Unbuzzd Common Share and (ii) one Unbuzzd Warrant. Each Unbuzzd Warrant entitles
the holder to acquire one additional Unbuzzd Common Share on or before July 25, 2027, for 115% of the Liquidity
Event Price.
The conversion price (“Unbuzzd Secured Debenture Conversion Price”) is equal to:
i)
ii)
iii)
US$0.05 per Unbuzzd Unit;
In the event of a Qualified Financing, then 0.80 multiplied by the Qualified Financing Price; or
In the event of a Liquidity Event, then 0.80 multiplied by the Liquidity Event Price:
Following the completion of a Qualified Financing or immediately prior to a Liquidity Event, Unbuzzd shall have the
option to force a conversion of the principal amount of each Unbuzzd Secure Debenture, and if Unbuzzd elects, the
accrued but unpaid Interest, into Units at the Conversion Price.
Qualified Financing means the completion of an equity financing by Unbuzzd, including but not limited to a Series A
financing, after the date hereof for aggregate gross proceeds of not less than US$500,000. Liquidity Event means a
takeover transaction or going public transaction.
The Unbuzzd Secured Debenture is collateralized by a priority security interest in substantially all assets of Unbuzzd
pursuant to the terms of a general security agreement.
22
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Conversion feature
The fair value of the conversion feature is determined by using with-and-without method that considers the change in
expected cash flows due to the conversion. The model includes all terms of the convertible debenture described above
as well as the probability of conversion and the implied credit spread of Unbuzzd. Expected volatility was estimated by
using historical volatility of Quantum as Unbuzzd considers it comparable for its own trading and volatility history. The
share price of $0.00017 (C$0.00025) was deemed reasonable by management based on Unbuzzd’s latest financing
price with arms-length parties. The fair value of the conversion feature as at the date of issuance and March 31, 2026,
was $Nil (December 31, 2025 - $Nil). The fair values were determined using the assumptions below:
Share price (USD)
Conversion price (USD)
Expected Volatility
Risk free interest rate
Expected life (years)
Credit Spread
Foreign exchange rate
July 25, 2025
$0.00017
$0.05000
168.20%
2.77%
1.00
25%
1.37
December 31, 2025
$0.00017
$0.05000
146.51%
2.55%
0.56
25%
1.37
March 31, 2026
$0.00017
$0.05000
157.45%
2.79%
0.32
25%
1.39
As of March 31, 2026, the Company had the following total debentures balance outstanding for the secured and
unsecured tranches:
Proceeds
Initial recognition of debt
Accretion expense
Balance, March 31, 2026,
and December 31, 2025
Unsecured
$ 334,955
$ 334,955
Secured
$ 122,222
$ 122,222
Total
$ 457,177
$ 457,177
14,833
487
15,320
349,788
$ 122,709
$ 472,497
$
Warrant liability
During the year ended December 31, 2025, Unbuzzd issued warrants attached to its convertible debentures.
Unbuzzd determined that these warrants were exchangeable into a variable number of shares due to foreign exchange,
and as such, the warrants were classified as financial liabilities measured at fair value through profit or loss (“FVTPL”).
Unbuzzd uses the Black-Scholes pricing model to estimate fair value. Expected volatility was estimated by using
historical volatility of other companies that the Unbuzzd considers comparable that have trading and volatility history.
The risk-free interest rate for the life of the warrants was based on the yields available on government benchmark
bonds with a term approximating the remaining term of the warrants. The life of the warrants is based on the contractual
term. The fair value of the warrant liability on dates of issuance for both secured and unsecured convertible debentures
issued was $Nil. The fair value of these warrants as of March 31, 2026, was also $Nil (December 31, 2025 - $Nil).
The fair value of the unsecured debenture warrants was determined using the Black-Scholes option pricing model and
the following assumptions as at:
Share price (USD)
Exercise price (USD)
Expected dividend yield
Risk free interest rate
Expected life (years)
Expected volatility
Foreign exchange rate
23
April 15,
2025
$0.00017
$0.15000
2.54%
2.00
119.78%
1.39
July 7,
2025
$0.00017
$0.15000
2.69%
1.77
132.95%
1.37
August/September
2025
$0.00017
$0.15000
2.49%-2.69%
1.57-1.69
136.82-%141.83%
1.38
October/November
2025
$0.00017
$0.15000
2.46%-2.47%
2.13-2.25
124.06%-127.63%
1.40
December 31,
2025
$0.00017
$0.15000
2.55%
2.00
135.29%
2.00
March 31, 2026
$0.00017
$0.15000
2.79%
1.785
149.24%
1.75
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
The fair value of the secured debenture warrants was determined using the Black-Scholes option pricing model and
the following assumptions as at:
Share price (USD)
Exercise price (USD)
Expected dividend yield
Risk free interest rate
Expected life (years)
Expected volatility
Foreign exchange rate
July 25, 2025
$0.00017
$0.15000
—
2.77%
2.00
168.20%
1.37
December 31, 2025
$0.00017
$0.15000
—
2.55%
1.56
146.51%
1.37
March 31, 2026
$0.00017
$0.15000
—
2.79%
1.32
157.45%
1.39
- Share capital
[a] Authorized
The Company is authorized to issue an unlimited number of class A multiple voting shares ("Class A Multiple Voting
Shares") and an unlimited number of Class B Subordinate Voting Shares, all without par value. All shares are ranked
equally regarding the Company's residual assets.
The Class B Subordinate Voting Shares are “restricted securities” within the meaning of such term under applicable
Canadian securities laws, as these securities do not carry equal voting rights as compared with the Class A Multiple
Voting Shares.
The holders of Class A Multiple Voting Shares are entitled to 276,660 votes per Class A Multiple Voting Share held.
Class A Multiple Voting Shares are held by the Chief Executive Officer (“CEO”), President, Executive Co-Chairman of
the Board and the Director and Executive Co-Chairman of the Board. The holders of Class B Subordinate Voting Shares
are entitled to one (1) vote per share held.
[b] Issued and outstanding
Reconciliation of the Company’s share capital is as follows:
Balance, December 31, 2024
Shares issued - convertible
debentures [a, b]
Exercise of options [c]
Warrants issued [d,e,f]
Warrants expired [g]
Balance, March 31, 2025
Balance, December 31, 2025
Shares issued - convertible
Debentures [h]
Warrants issued [i]
Exercise of RSUs [j]
Shares issued for debt [k]
Shares issued [l]
Warrants expired [m]
Balance, March 31, 2026
24
Class A shares
$
12
151,701
Class B shares
$
2,299,502
150,318,624
Warrants
210,370
$
1,997,759
—
—
—
—
12
—
—
—
—
151,701
399,071
12,500
—
—
2,711,073
2,495,090
70,591
—
—
152,884,305
—
—
346,806
(30,770)
526,406
—
—
—
(618,578)
1,379,181
42
152,247
3,887,729
169,551,044
32
10,009
—
—
—
—
—
—
42
—
—
—
—
—
—
152,247
16,748
—
44,415
370,457
1,536,341
—
5,855,690
88,978
—
1,458,141
839,896
5,395,700
—
177,333,759
—
1,249,984
—
—
—
(32)
1,249,984
—
—
—
—
—
(10,009)
—
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Activity during the three months ended March 31, 2025:
[a] On February 7, 2025, a partial amount of the January 2025 Debentures was converted into an aggregate of
152,577 Class B Subordinate Voting Shares (Note 12). On February 26, 2025, the remaining amount was
converted into an aggregate of 221,237 Class B Subordinate Voting Shares (Note 12). Thus, the total number
of Class B Subordinate Voting Shares issued upon conversion of the January 2025 Debentures was 373,814
with a total value of $2,463,902 transferred to share capital.
[b] On March 25, 2025, the full amount of the March 6, 2025 Debenture of $100,000 was converted into an
aggregate of 25,257 Class B shares with a value of $31,188 (Note 12).
[c] During the three months ended March 31, 2025, the Company issued an aggregate of 12,500 Class B shares
upon the exercise of 12,500 share options with an exercise price C$5.25 for total gross proceeds of $45,887.
Total amount of $70,591 was transferred to share capital. The market prices on the dates of option exercise
ranged between $8.56 to $11.32 per share.
[d] During the three months ended March 31, 2025, 152,577 warrants of the Company were issued as part of the
issuance of January 2025 Debentures (Note 12).
[e] During the three months ended March 31, 2025, 10,309 warrants of the Company were issued as part of the
issuance of March 6, 2025 Debentures (Note 12).
[f]
During the three months ended March 31, 2025, 183,920 warrants of the Company were issued as part of the
issuance of March 28, 2025 Debentures (Note 12).
[g] During the three months ended March 31, 2025, 30,770 warrants expired unexercised.
Activity during the three months ended March 31, 2026
[h] On March 31, 2026, a partial amount of the March 2026 Debentures was converted into an aggregate of
16,748 Class B Subordinate Voting Shares with a total value of $88,978 transferred to share capital (Note 13).
[i] During the three months ended March 31, 2026, 1,249,984 warrants of the Company were issued as part of
the issuance of March 2026 Debentures (Note 12).
[j] During the three months ended March 31, 2026, 96,000 RSUs were exercised into 44,415 Class B
Subordinate Voting Shares, which were issued to non-arm’s length parties (Note 20). Total of $1,458,141 was
transferred to share capital.
[k] During the three months ended March 31, 2026, the Company settled an aggregate of $839,896 amounts
owing to various creditors, through the issuance of 370,457 Class B Subordinate Voting Shares at price of
$2.27 (C$3.11) per Class B Subordinate Voting Share. Of the total shares issued, 300,000 Class B
Subordinate Voting Shares valued at $680,157 were issued to settle a bonus accrual of $645,570 owing to
management of the Company (Note 20). The Company incurred a net loss on settlement of debt of $35,802
during the three months ended March 31, 2026.
[l] During the three months ended March 31, 2026, pursuant to the ATM agreement, the Company issued
1,536,341 common shares for a total increase in share capital of $5,395,700, of which gross proceeds of
$5,553,296 were received. A total cash commission of $138,832 based on 2.50% of the aggregate gross
proceeds, plus other trading expenses of $18,764 resulted in total share issuance costs of $157,596.
[m] During the three months ended March 31, 2026, 32 warrants expired unexercised.
25
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
The changes in the number of warrants outstanding during the three months ended March 31, 2026, and 2025:
Outstanding as at December 31, 2025
Issued
Expired
Outstanding as at March 31, 2026
Number of warrants
32
1,249,984
(32)
1,249,984
Weighted average
exercise price
C$
1,737.65
3.75
1,737.65
3.75
Outstanding as at December 31, 2024
Issued
Expired
Outstanding as at March 31, 2025
Number of warrants
210,370
346,806
(30,770)
526,406
Weighted average
exercise price
C$
250.33
6.18
5.33
83.83
Measurement of fair values
During the three months ended March 31, 2026, a total of 1,249,984 warrants of the Company were issued in
connection with the issuance of the March 2026 Debentures (Note 12). These warrants are classified as derivative
liabilities (Note 10(f)).
During the three months ended March 31, 2025, a total of 346,806 warrants of the Company were issued in connection
with the issuance of the January 2025 Debentures, March 6, 2025 Debentures, and March 28, 2025 Debentures (Note
12). These warrants are classified as derivative liabilities (Note 10(b-e)).
There were no warrants issued during the three months ended March 31, 2026, and 2025 under equity.
The following table is a summary of the Company’s warrants outstanding as at March 31, 2026:
Expiry Date
March 20, 2031
Exercise price
C$
3.75
3.75
Number outstanding
1,249,984
1,249,984
- Share-based compensation
The Company has established a share option plan (the “Option Plan”) for directors, officers, employees and consultants
of the Company. The Company’s Board determines, among other things, the eligibility of individuals to participate in
the Option Plan, the term and vesting periods, and the exercise price of options granted to individuals under the Option
Plan.
Each share option is converted into one Class B Subordinate Voting Share on exercise. No amounts are paid or payable
by the individual on receipt of the option. The options carry neither rights to dividends nor voting rights. Options may
be exercised at any time from the date of vesting to the date of their expiry.
26
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
[i] Share-based payment arrangements
During the three months ended March 31, 2026, the Company granted a total of 35,000 (2025 – 57,692) share options.
Each option granted vests immediately and is exercisable at a price of CA$6.50 for a period of five years from the issue
date.
During the three months ended March 31, 2025, 12,500 share options were exercised for total gross proceeds of
$45,887. The total contributed surplus of $24,704 was transferred share capital.
The changes in the number of share options outstanding during the periods ended March 31, 2026, and 2025 are as
follows:
Outstanding as at December 31, 2025
Granted
Expired
Outstanding as at March 31, 2026
Exercisable as at March 31, 2026
Number of options
160,956
35,000
(456)
195,500
195,500
Weighted average
exercise price
C$
6.97
6.50
155.47
16.34
16.34
Outstanding as at December 31, 2024
Granted
Exercised
Outstanding as at March 31, 2025
Exercisable as at March 31, 2025
Number of options
42,456
57,692
(12,500)
87,648
83,481
Weighted average
exercise price
C$
6.97
9.46
5.25
8.85
9.01
Measurement of fair values
The fair value of share options granted during the three months ended March 31, 2026, and 2025, were estimated at
the date of grant using the Black-Scholes option pricing model with the following inputs:
Grant date share price
Exercise price
Expected dividend yield
Risk free interest rate
Expected life
Expected volatility
2026
C$6.62
C$6.50
—
3.18%
5 years
122%
2025
C$6.64-C$9.92
C$6.60-C$9.90
—
2.60%-2.61%
2 years
132%-136%
Expected volatility was estimated by using the annualized historical volatility of the Company. The expected option life
represents the period that options granted are expected to be outstanding. The risk-free interest rate is based on
Canadian government bonds with a remaining term equal to the expected life of the options.
The following table is a summary of the Company’s share options outstanding as at March 31, 2026:
27
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Exercise price
C$
5.60
9.90
24.50
6.50
16.34
Number
outstanding
12,500
50,000
98,000
35,000
195,500
Weighted average
remaining contractual
life [years]
0.44
0.99
4.49
4.99
3.43
Exercise price
C$
5.60
9.90
24.50
6.50
16.34
Number
exercisable
12,500
50,000
98,000
35,000
195,500
[ii] Performance Share Units (“PSUs”) and Restrictive Share Units (“RSUs”)
In May 2022, the Company established a performance share unit plan (“PSU Plan”) and a restrictive unit plan (“RSU
Plan”), for directors, offers, employees and consultants of the Company. The Company’s Board determines the eligibility
of individuals to participate in the PSU Plan and RSU Plan to align their interests with those of the Company’s
shareholders.
No amounts are paid or payable by the individual on receipt of the PSUs and RSUs. Each PSU and RSU convert into
one Class B Subordinate Voting Share at $Nil exercise price. The Company’s PSU Plan and RSU Plan provides that
the number of Class B Subordinate Voting Shares reserved for issuance may not exceed 10% of the aggregate number
of Class B Subordinate Voting Shares that are outstanding unless the Board has increased such limit by a Board
resolution.
PSUs
There were no PSUs issued during the three months ended March 31, 2026, and 2025. As at March 31, 2026, there
were no PSUs outstanding (December 31, 2025 - Nil).
RSUs
On August 23, 2024, the Company granted an aggregate of 32,690 RSUs at a price of $4.21 per unit for a total value
of $137,625 based on the share price at the date of issuance. Each RSU granted vests the earlier of: (i) one year; and
(ii) the successful implementation of the MS MAD study conducted by Ingenu of Australia, subject to acceleration in
the event of a takeover bid or change of control. During the three months ended March 31, 2026, the Company
recognized $Nil (2025 - $33,963) as share-based compensation expense and contributed surplus. As at March 31,
2026, there were no RSUs outstanding as the total 32,690 RSUs were exercised and converted into 32,690 Class B
Subordinate Voting Shares during the year ended December 31, 2025.
On August 15, 2025, the Company granted a total of 1,600 RSUs to two individuals for 800 RSUs each, with the
following vesting conditions:
First Vesting Tranche of 500 RSUs: i. The filing of an investigational new drug (“IND”) application with the U.S. FDA,
or an equivalent regulatory filing in another country for the start of a clinical trial for Lucid-MS. This condition must be
met within one year of the date of this resolution. If not achieved within one year, no RSUs vest under this tranche.
Second Vesting Tranche of 300 RSUs: i. Receipt of a no-objection letter or an equivalent regulatory approval from the
U.S. FDA or other regulatory institution permitting the commencement of the clinical trial associated with the IND filing
in the First Vesting Tranche.
During the three months ended March 31, 2026, the Company recognized $8,857 (2025 - $Nil) as share-based
compensation expense related to the portion vested using a price of $22.45 on the date of issuance.
28
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
On September 26, 2025, the Company granted 96,000 RSUs at a price of $16.32 per unit with a maturity of March 31,
2026. During the three months ended March 31, 2026, 96,000 RSUs were exercised and converted into 44,415 Class
B Subordinate Voting Shares. The Company recognized a value of $741,059 as share-based compensation expense
related to the vested portion up to March 11, 2026, the date of exercise.
The change in the number of RSUs during the periods ended March 31, 2026, and 2025, is as follows:
Outstanding as at December 31, 2025
Converted to common shares
Outstanding as at March 31, 2026
Number of RSUs
97,600
(96,000)
1,600
Outstanding as at December 31, 2024
Granted
Converted to common shares
Outstanding as at March 31, 2025
Number of RSUs
32,690
32,690
The Company recognized share-based compensation as follows for the three months ended March 31, 2026, and
2025:
Share options
RSUs (i)
(i)
2026
$
139,767
752,290
892,057
2025
$
257,309
33,963
291,272
Includes $2,374 share-based compensation from Unbuzzd for the three months ended March 31, 2026.
- Non-controlling interests
Through the License Agreement, Quantum acquired 34.66% of Unbuzzd on July 31, 2023. As of March 31, 2026, the
Company had a 19.84% (December 31, 2025 – 19.84%) ownership interest in Unbuzzd through Unbuzzd Common
Shares. The non-controlling interest represents the Unbuzzd Common Shares not attributable to the Company.
Reconciliation of non-controlling interest is as follows:
Balance, December 31, 2025
Net loss for the period
Balance, March 31, 2026
$
(1,821,860)
(193,265)
(2,015,125)
The condensed consolidated interim financial statements incorporate the assets and liabilities of Unbuzzd as of March
31, 2026.
16. Loss per share
Net loss per common share represents net loss attributable to common shareholders divided by the weighted average
number of common shares outstanding during the period.
29
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
For all the periods presented, diluted loss per share equals basic loss per share due to the anti-dilutive effect of
warrants, share options, PSUs, RSUs and convertible debentures. The outstanding number and type of securities that
could potentially dilute basic net loss per share in the future but would have decreased the loss per share (anti-dilutive)
for the three months ended March 31, 2026, and 2025 are as follows:
Warrants
Share Options
RSUs
Convertible debentures
March 31, 2026
1,249,984
195,500
1,600
1,233,334
2,680,418
March 31, 2025
526,406
87,648
32,690
547,285
1,194,029
- General and administrative
Components of general and administrative expenses for the three months ended March 31, 2025, and 2024 were as
follows:
Professional fees
Investor relations
Salaries, wages and benefits
Consulting fees
Office and general administrative
Foreign exchange loss
2026
$
295,401
123,757
429,303
192,688
222,758
56,813
1,320,720
2025
$
355,722
358,901
337,839
125,144
138,705
11,800
1,328,111
- Segment information
Reportable segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision maker, with appropriate aggregation. The chief operating decision maker is the CEO who is responsible for
allocating resources, assessing the performance of the reportable segment and making key strategic decisions. The
Company operates in one segment, Biopharmaceutical, which is focused on furthering the research and development
of the Company’s drug candidates and the development of a treatment for alcohol misuse for applications in hospitals
and other medical practices.
The Company’s Strategic Investments segment is no longer active as of March 31, 2026, and December 31, 2025.
The following tables summarize the Company's total current and non-current assets and current and non-current
liabilities as of March 31, 2026, and December 31, 2025, on a segmented basis:
As of March 31, 2026
Current assets
Non-current assets
Current liabilities
30
Biopharmaceutical
$
10,369,056
4,557,019
16,345,974
Total
$
10,369,056
4,557,019
16,345,974
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
As of December 31, 2025
Biopharmaceutical
$
6,478,353
4,682,556
6,058,294
Current assets
Non-current assets
Current liabilities
Total
$
6,478,353
4,682,556
6,058,294
The following tables summarize the Company's interest income, total operating expenses, and net loss for the three
months ended March 31, 2026, and 2025 on a segmented basis:
Interest expense (income)
Total operating expenses
Net (loss) income
For the three months ended March 31, 2026
Biopharmaceutical Strategic Investments
$
$
9,579
(517)
2,966,172
133
(13,753,948)
384
Interest expense (income)
Total operating expenses
Net (loss) income
For the three months ended March 31, 2025
Biopharmaceutical Strategic Investments
Total
$
$
$
(2,584)
(64,632)
(67,216)
3,397,101
322
3,397,423
(8,804,191)
64,310
(8,739,881)
Total
$
9,062
2,966,305
(13,753,564)
- Commitments and contingencies
Commitments
Lucid-MS Agreement
The Company has entered into a license agreement that governs the Lucid-MS compound. Under the terms of the
agreement, the Company shall pay a yearly license maintenance fee of C$50,000 until the first commercial sale of a
product is made.
Under the agreement the Company is committed to minimum milestone payments of $Nil and maximum milestone
payments of C$9,375,000 if all product development and regulatory milestones are met. Furthermore, the Company is
also responsible for paying revenue milestone payments and royalties if revenue milestones from commercial sales
are achieved. Milestones can be extended by mutual agreement. No payments have been made to date related to
these milestones.
31
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Contingencies
Legal Matters
From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory
and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimated at the
reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or
proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates,
the difference will be accounted for as a charge to the consolidated statements of loss and comprehensive loss in that
year.
GBB Drink Lab, Inc. (“GBB”)
On May 12, 2023, the Company announced that it had received a lawsuit filed in S.D. Fla. by GBB against the Company,
alleging breach of a mutual non-disclosure agreement and misappropriation of trade secrets. GBB claimed that its
assets were valued at US$53,047,000 as of August 30, 2022 (prior to the misappropriation and material breach).
On June 23, 2023, the Company filed a motion to dismiss the complaint. On July 3, 2023, GBB responded in opposition
to the Company’s motion to dismiss the complaint. On August 24, 2023, the parties filed a proposed joint scheduling
report with the S.D. Fla., which set forth various deadlines that would govern this action. Under the proposed joint
schedule, the case was supposed to be trial-ready by November 30, 2024. On January 8, 2024, the S.D. Fla. denied
the Company’s request to dismiss the lawsuit.
On January 22, 2024, the Company filed a third-party complaint against Joseph Romano (a former director of the
Company) and a counterclaim against GBB. The Company alleged that Mr. Romano breached his fiduciary duty by
providing or fabricating confidential information to GBB, and that GBB aided and abetted this breach. On October 9,
2024, Judge Melissa Damian denied Mr. Romano’s motion to dismiss, finding that the Company plausibly alleged
Romano breached fiduciary duties, including his duties of loyalty, confidentiality, and to act in the company’s best
interests. GBB and Romano then denied the allegations in their respective answers.
Discovery concluded in July 2025, and on July 21, 2025, the parties filed various pre-trial motions, including summary
judgment motions. On October 9, 2025, the Court granted the motion for the Company’s current counsel, Given Pursley
LLP, to appear, officially appointing them and relieving prior counsel, Blank Rome LLP. A status conference was held
on December 16, 2025, where the Court ruled on several pending motions. The Court granted Mr. Romano’s motion
for summary judgment, dismissing all claims against him. The Court reserved ruling on the Company’s motion for
summary judgment, ordering supplemental briefing on the issue of whether GBB has standing to pursue its claims after
selling its assets to a third party. The trial, previously set for January 2026, has been continued.
The parties filed supplemental briefs addressing standing in accord with the Court’s order. But GBB then filed a reply
brief. On February 17, 2026, the Company filed a motion to strike GBB’s reply brief and accompanying exhibits, arguing
that the filing was unauthorized. On February 18, 2026, GBB filed a response in opposition to the motion to strike. On
March 24, 2026, the Court denied the motion to strike, and the Court denied the Company’s motion for summary
judgment. Trial was set to begin the week of May 18, 2026, but the parties jointly have requested a sixty-day
continuance. No subsequent event occurred as of the date of this report.
Lawsuit against CIBC World Markets, RBC Dominion Securities, and John Does 1-10
On October 20, 2024, the Company filed a complaint in the U.S. District Court for the Southern District of New York
against CIBC World Markets, Inc., RBC Dominion Securities Inc., and John Does 1-10. The complaint alleges market
manipulation through spoofing activities between January 1, 2020, and August 15, 2024. The Company is seeking
damages of more than US$700 million. On May 1, 2025, the Company filed an amended complaint, in response to the
Motion to Dismiss filed by the banks on January 31, 2025.
32
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
The complaint alleges that between January 1, 2020, and August 15, 2024, the defendants engaged in "spoofing," an
unlawful trading practice, to manipulate the market price of Quantum's shares. The complaint details that the defendants
placed thousands of spoofing orders to sell, creating the illusion that Quantum's share price was declining. This practice
allegedly "tricked" other investors into selling their shares at lower prices, driving the company's share price downward.
The defendants then purchased shares at artificially depressed prices, positioning themselves to profit when the market
price rebounded. The Company claims to have suffered significant damage and seeks to recover more than USD $700
million. It alleges that it sold approximately 90 million shares of its stock on U.S. and Canadian exchanges during the
relevant period at artificially depressed prices due to the defendants' spoofing activities. The complaint names CIBC
World Markets, Inc., RBC Dominion Securities Inc., and John Does 1 through 10 as defendants. It asserts three claims
for relief: violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5(a) and (c), violation of
Section 9(a)(2) of the Securities Exchange Act of 1934, and New York Common Law Fraud.
The defendants filed a motion to dismiss on June 16, 2025. On March 30, 2026, the United States District Court for the
Southern District of New York largely ruled against defendants. Subsequent to March 30, 2026, no further events
occurred as of the date of this report.
20. Related party transactions
Related parties and related party transactions impacting the condensed consolidated interim financial statements are
summarized below and include transactions with the following individuals or entities:
Key management personnel
Related parties include directors, officers, close family members, certain consultants and enterprises that are controlled
by these individuals as well as certain individuals performing similar functions.
Key management personnel are those individuals who have authority and responsibility for planning, directing and
controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of
the Company.
Transactions with key management and directors comprise the following:
a)
b)
c)
d)
e)
33
Director’s compensation for the three months ended March 31, 2026, is $30,848 (2025 – $29,587).
During the three months ended March 31, 2026, the Company granted 5,000 (2025 – 57,692) options to an
officer of the Company with an exercise price of $6.50 (2025 - C$6.60 to C$9.90) and expiring five years (2025
– two years) from the date of issuance.
During the three months ended March 31, 2026, the Company issued a total of 300,000 Class B Subordinate
Voting Shares related to management bonuses of $645,570 accrued as of December 31, 2025 (Note 13).
Of the 3,750 March 2026 Debenture Units, 300 March 2026 were issued to a related party of the Company,
who is a director of the Company, and 1,400 March 2026 Debenture Units were issued to an entity, which is
owned by a family member of the CFO of the Company. (Note 12).
During the year ended December 31, 2025, the Company entered into a lease agreement with Peak Corp, an
entity, which is owned by a family member of the CFO of the Company. The lease arrangement had resulted
in the right-of-use asset recognized as at December 31, 2025, of $102,320. The lease term ends on June 30,
2027. During the three months ended March 31, 2026, the Company paid an aggregate of C$27,120 for
monthly installments in accordance with the lease arrangement.
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Key management personnel compensation during the three months ended March 31, 2026, and 2025, is comprised of:
Salaries, benefits, bonuses and consulting
fees
Share-based payments
2026
$
2025
$
217,665
761,025
978,690
208,132
1,316,483
1,524,615
As at March 31, 2026, the Company has $Nil (December 31, 2025 - $645,570) owing to related parties related to bonus
accruals included in accounts payable and accrued liabilities.
- Capital Management
The Company defines capital as the aggregate of its capital stock and borrowings and convertible debentures.
As at March 31, 2026, the Company’s share capital was $177,486,006 (December 31, 2025 – $169,703,291). The
Company does not have any long-term debt.
The Company manages its capital structure in accordance with changes in economic conditions. To maintain or adjust
its capital structure, the Company may elect to issue or repay financial liabilities, issue shares, repurchase shares or
undertake any other activities as deemed appropriate under specific circumstances. The Company is not subject to any
externally imposed capital requirements. There were no changes in capital management during the periods ended
March 31, 2026, and 2025.
- Financial Instruments and Risk Management
Credit risk
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to
meet its contractual obligations and arises principally from deposits with banks and outstanding other receivables and
finance receivables. The Company trades only with recognized, creditworthy third parties.
The Company does not hold any collateral as security for its outstanding finance receivables but mitigates this risk by
dealing only with what management believes to be financially sound counterparties and, accordingly, does not
anticipate significant loss for non-performance. The loans are secured by real estate properties, and the Company is
granted a first or second collateral charge mortgage on the properties for a sum equal to the interest payments plus
the principal amount. The Company performs assessments on factors such as timing of payments, loan to value,
communications with the borrower and external macro factors such as interest rates and economic conditions to
mitigate risks.
Liquidity risk
Liquidity risk is the risk the Company will not be able to meet its financial obligations as they come due. The Company’s
exposure to liquidity risk is dependent on the Company’s ability to raise additional financing to meet its commitments
and sustain operations. The Company mitigates liquidity risk by management of working capital, cash flows, the
issuance of share capital and if desired, the issuance of debt. The Company’s trade and other payables and notes
payables are all due within twelve months from the date of these financial statements.
If unanticipated events occur that impact the Company’s ability to carry out the planned clinical trials, the Company
may need to take additional measures to increase its liquidity and capital resources, including issuing debt or additional
equity financing or strategically altering the business forecast and plan. In this case, there is no guarantee that the
34
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
Company will obtain satisfactory financing terms or adequate financing. Failure to obtain adequate financing on
satisfactory terms could have a material adverse effect on the Company’s results of operations or financial condition.
Market risk
Market risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in
market prices. Market risk comprises three types of risk: foreign currency risk, interest rate risk and other price risk.
•
Foreign currency risk
Foreign currency risk arises with financial instruments that are denominated in a currency other than the
functional currency in which they are measured. The Company’s primary exposure with respect to foreign
currencies is from Canadian dollar denominated cash, investments and trade and other payables. A 1%
change in the foreign exchange rates would not have any significant impact on the condensed consolidated
interim financial statements.
•
Interest rate risk
Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of
changes in market interest rates. The Company does not have any material long-term borrowings outstanding
subject to variable interest rates. Therefore, the Company is not exposed to interest rate risk as at March 31,
2026.
•
Other price risk
Other price risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of
changes in market prices (other than those arising from interest rate risk or currency risk), whether those
changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting
all similar financial instruments traded in the market. The Company is not exposed to other price risks as at
March 31, 2026.
Fair values
The carrying values of cash, other receivables (excluding sales tax recoverable), trade and other payables, and notes
payable approximate fair values due to the short-term nature of these items, or they are being carried at fair value or,
for, notes payable, interest payables and convertible debentures are close to the current market rates. The risk of
material change in fair value is not considered to be significant. The Company does not use derivative financial
instruments to manage this risk.
Financial instruments recorded at fair value on the condensed consolidated interim statements of financial position are
classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The
Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the
inputs used by the Company’s valuation techniques. A level is assigned to each fair value measurement based on the
lowest-level input significant to the fair value measurement in its entirety. The three levels of the fair value hierarchy
are defined as follows:
35
•
Level 1 – Unadjusted quoted prices as at the measurement date for identical assets or liabilities in
active markets.
•
Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for
similar assets and liabilities in active markets; quoted prices for identical or similar assets and
liabilities in markets that are not active; or other inputs that are observable or can be corroborated by
observable market data.
•
Level 3 – Significant unobservable inputs that are supported by little or no market activity. The fair
value hierarchy also requires an entity to maximize the use of observable inputs and minimize the
use of unobservable inputs when measuring fair value.
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
Notes to the condensed consolidated interim financial statements
[unaudited] [expressed in United States dollars]
For the three months ended March 31, 2026, and 2025
The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument
is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.
Investments are measured using level 1 and level 2 inputs. Digital assets, warrant liabilities and derivative liabilities are
measured using level 2 inputs. During the three months ended March 31, 2026, there were no transfers of amounts
between levels.
23. Subsequent events
36
•
Subsequent to March 31, 2026, the Company successfully sold an aggregate of $1,424,482 in gross proceeds
under its at-the-market offering agreement with Rodman and Renshaw LLC, as sales agent.
•
On April 16, 2026, the Company issued 94,408 Class B Subordinate Voting Shares to one investor, upon the
conversion of a convertible debenture, pursuant to the March 2026 Debenture Units
•
On April 28, 2026, the Company issued 84,702 Class B Subordinate Voting Shares to one investor, upon the
conversion of a convertible debenture, pursuant to the March 2026 Debenture Units.